Metagenomi Therapeutics (MGX) closed at $0.61 on November 19, 2026, down 2.9% from the previous close, on volume of 123,157 shares (30-day average 172,974).
Data as of November 19, 2026.
Metagenomi Highlights MGX-001 Hemophilia A Gene Editing Program
TipRanks (Mon, 16-Nov 5:31 PM ET)
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London
Globe Newswire (Wed, 11-Nov 8:00 AM ET)
Globe Newswire (Tue, 10-Nov 4:05 PM ET)
Globe Newswire (Wed, 4-Nov 9:25 AM ET)
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
Globe Newswire (Tue, 13-Oct 8:00 AM ET)
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Globe Newswire (Tue, 1-Sep 8:00 AM ET)
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Tue, 25-Aug 10:13 AM ET)
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
Metagenomi Therapeutics trades on the NASDAQ stock market under the symbol MGX.
As of November 19, 2026, MGX stock price declined to $0.61 with 123,157 million shares trading.
MGX has a beta of 1.92, meaning it tends to be more sensitive to market movements. MGX has a correlation of 0.24 to the broad based SPY ETF.
MGX has a market cap of $23.19 million. This is considered a Sub-Micro Cap stock.
Last quarter Metagenomi Therapeutics reported $2 million in Revenue and -$.56 earnings per share. This beat revenue expectation by $124,000 and exceeded earnings estimates by $.08.
The top ETF exchange traded funds that MGX belongs to (by Net Assets): VTI, VXF, IWC, BUSM.
MGX has underperformed the market in the last year with a price return of -63.9% while the SPY ETF gained +9.6%. MGX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -49.3% and -22.3%, respectively, while the SPY returned -6.5% and -6.6%, respectively.
MGX support price is $.59 and resistance is $.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MGX shares will trade within this expected range on the day.